Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Servier: Precision Approach To Immunotherapy Will Define New Oncology Era

Executive Summary

Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.

You may also be interested in...



Architect Of Keytruda Reflects On A Great Scientific Success Story

Eric Rubin, who heads up early oncology clinical development at Merck Research Laboratories, tells Scrip that it became clear very early on that Keytruda was something special.

Cost Of Providing CAR-T Therapies Could Derail Reimbursement In England

Gilead claims that the mechanism used to work out the cost for the National Health Service in England of delivering CAR-T therapies to patients could threaten access to these medicines.

Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases

Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC147108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel